Technology

10x Genomics Unveils Innovation Roadmap at AGBT General Meeting, Advancing Leadership in Large-Scale Single Cell and Spatial Analysis

Published

1 year ago

February 23, 2025

New single cell and spatial innovations extend 10x Genomics’ technology and performance
leadership across all three platforms

PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for high-performance single cell research at scale. In addition, the company unveiled a robust new product roadmap for its Visium and Xenium portfolios, extending its performance and technology leadership in the rapidly growing field of spatial biology.

“After a record year of innovation, we continue to push the boundaries of what’s possible in single cell and spatial biology, taking on the hardest challenges so researchers can make the biggest impact,” said Ben Hindson, Co-Founder and Chief Scientific Officer of 10x Genomics. “Our 2025 roadmap will once again raise the bar for the field and enable researchers to tackle bigger questions, analyze more samples and extract deeper insights from their data.”

10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1 p.m. ET to share the latest data and development directions across its three platforms. This workshop will be live-streamed beginning at 1:30 p.m. ET for researchers not attending AGBT.

Advancing Large-Scale Single Cell Research

Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use. Highlights of 10x’s forthcoming innovations in single cell analysis include:

Plate-based workflows for Chromium GEM-X Flex: The company announced plans for plate-based GEM-X Flex workflows designed to massively expand the number of samples per run. At launch, this plate-based workflow will enable more than 700 samples in a single run. Researchers will be able to use plate-based GEM-X Flex to recover approximately 1 million cells from a single lane and 8 million cells per chip. Unlike alternative offerings, the plate-based approach on GEM-X Flex will be a highly parallel workflow that does not require using an entire plate at once, giving researchers full control and flexibility over how they design and scale their studies. Researchers will also be able to partition millions of cells in minutes using Chromium X and iX instruments as part of this plate-based workflow.

Optimized for a wide range of large-scale studies, including perturbation screens and large sample cohorts, the GEM-X Flex plate-based workflow is expected to deliver top-tier sensitivity, high quality data and best-in-class sequencing efficiency to ensure superior results at scale.

10x Cloud Analysis for Large Studies will give researchers even more scalable ways to manage large datasets, including a new batch analysis feature for running hundreds or thousands of analyses in parallel. 10x Genomics Cloud Analysis already provides researchers with access to robust computational resources in a simple web interface. Cloud Analysis for Large Studies will help researchers looking to automate data processing programmatically while taking advantage of 10x Cloud’s high-performance infrastructure. These capabilities will be available to support both the Chromium and Visium platforms.

Once launched, these offerings will join a broad portfolio of recent Chromium innovations intended to democratize access to single cell analysis by delivering high performance and low cost at any scale. These include:

GEM-X Flex Gene Expression, which enables mega-scale single cell research for as low as one cent per cell.GEM-X Universal Multiplex, featuring on-chip multiplexing so researchers can easily batch and run four independent samples, up to 5,000 cells per sample, for approximately $600 per sample, at any scale.Chromium Xo, a high-powered instrument at a low-cost entry point so more researchers can access the performance and workflow advantages of Chromium single cell analysis.

Expanding Technology Leadership in Spatial Biology

10x Genomics continues to lead the spatial biology revolution with a broad portfolio of easy-to-use technologies that enable superior performance and provide deeper, high resolution insights into tissue organization and function.

Visium Platform

In 2024, 10x Genomics launched its groundbreaking Visium HD product, increasing the resolution of the Visium platform by over three orders of magnitude. Now compatible with FFPE, Fresh Frozen and Fixed Frozen tissues, Visium HD delivers high sensitivity and sequencing efficiency with the proven CytAssist-enabled workflow. 10x Genomics revealed today several planned additions to the Visium HD platform, including:

Visium HD 3′ for high resolution, species-agnostic spatial profiling: 10x Genomics unveiled its plans to bring its flagship Visium v1 3′ assay, launched in 2019, into high resolution with improvements in both performance and workflow. The forthcoming Visium HD 3′ assay is a reverse transcription-based approach to whole transcriptome spatial profiling at single cell scale. Visium HD 3′ is designed to enable de novo discovery across a broad range of applications, such as analysis of isoforms and long non-coding RNAs. Visium HD 3′ will deliver both high resolution and high sensitivity in a diverse set of species and a wide range of fresh frozen tissues. Powered by Visium CytAssist, Visium HD 3′ will give researchers a streamlined workflow featuring same-section H&E staining on standard glass slides and no tissue optimization required.

Visium HD Cell Segmentation for morphology-guided spatial transcriptomics: Visium HD Cell Segmentation leverages H&E images from the same tissue section and high spatial fidelity enabled by CytAssist to resolve spatial transcriptomics data at single-cell scale. This approach enables researchers to assign transcripts to individual cells with precision, improving clustering and characterization of cellular heterogeneity within tissues. By integrating gene expression with morphology-driven segmentation, researchers can uncover new cell populations and spatial interactions that were previously masked.

Visium HD XL: The company also highlighted Visium HD XL, which will feature an expanded capture area to enable whole transcriptome spatial gene expression analysis of larger tissue sections at single-cell-scale resolution.

Xenium Platform

Xenium RNA+Protein Multiomics: 10x Genomics shared plans to enable simultaneous detection of RNA and proteins on the same slide and tissue section to unlock multiomic insights into cellular function at subcellular resolution. In a single Xenium run, researchers will be able to seamlessly integrate RNA and proteins and preserve the high data quality they have come to expect from the platform. The validated plug-and-play protein immunology panel for human FFPE tissues will include seven modular subpanels covering up to 28 protein targets to eliminate the burden of assay development and optimization. It is designed to complement a broad Xenium menu of curated, semi-custom and fully custom RNA v1 panels to maximize data quality and workflow efficiency.

10x Genomics at AGBT

Throughout AGBT, 10x Genomics will host a series of scientific presentations and events to showcase how its latest technologies are driving biological discovery:

Pre-Conference Workshop: Revving up insights in single cell and spatial exploration (February 23, 2025). Register for the livestream here.Featured Posters:Poster 457: GEM-X Universal Multiplex: A cost-effective, sample- and species- agnostic multiplexing approach for single-cell RNA sequencingPoster 439: In Situ detection of HPV expression in human cervical cancer with Xenium Prime 5KPoster 432: Exploring tumor microenvironment heterogeneity through multiomic In Situ profiling of RNA and proteins

About 10x Genomics

10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world’s understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which fall under the “safe harbor” provisions of those sections. All statements, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.’s (“10x Genomics”) product launches, performance, scale, configuration, costs, capabilities, adoption and pipeline. These statements are based on management’s current expectations, forecasts, beliefs, assumptions and information currently available to management, and actual outcomes and results could differ materially from these statements due to a number of factors. Other risks and uncertainties that could affect 10x Genomics’ financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents 10x Genomics files with the Securities and Exchange Commission (the “SEC”) from time to time. Although 10x Genomics believes that the expectations reflected in the forward-looking statements are reasonable, it cannot provide any assurance that these expectations will prove to be correct nor can it guarantee that the future results, levels of activity, performance and events and circumstances reflected in the forward-looking statements will be achieved or occur. The forward-looking statements in this press release are based on information available to 10x Genomics as of the date hereof, and 10x Genomics disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing 10x Genomics’ views as of any date subsequent to the date of this press release.

Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

Contacts
Investors: investors@10xgenomics.com
Media: media@10xgenomics.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-unveils-innovation-roadmap-at-agbt-general-meeting-advancing-leadership-in-large-scale-single-cell-and-spatial-analysis-302382827.html

SOURCE 10x Genomics, Inc.

Technology

Zifo Transforms Ontology Engineering with AI-Powered Intelligent Automation

Published

12 minutes ago

April 30, 2026

Advanced AI solution speeds up ontology creation by 80%, generating structured, interoperable knowledge models for science-driven organizations.

CAMBRIDGE, Mass. and CAMBRIDGE, England, April 30, 2026 /PRNewswire/ — Zifo, the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations, has developed an Intelligent Automation solution for Ontology Engineering, which is designed to seamlessly generate structured, interoperable knowledge models while accelerating ontology creation by 80%.

Overcoming the Bottlenecks of Manual Ontology Creation

Manual ontology creation in the biopharma industry has traditionally been a time-consuming process that requires specialized expertise. Organizations frequently struggle with semantic ambiguity, complex integration challenges, and limited scalability, resulting in workflows that can take weeks to complete. Zifo’s AI-powered automation tackles these challenges head-on by eliminating 80% of the manual work through automated class generation, description creation, and precise IRI mapping.

Addressing the Complexities of Semantic Knowledge

Developing comprehensive knowledge models often demands deep domain expertise to define relationships and align terminology. Zifo’s intelligent solution overcomes this by providing an AI-guided workflow featuring an intuitive interface, meaning specialized ontology engineering knowledge is no longer required. By leveraging LLM-powered generation, the solution creates precise definitions with a deep understanding of domain-specific context, while generating standardized synonyms and establishing controlled vocabulary alignment to eliminate inconsistent terminology.

A Solution Designed for Scalable Scientific Data Modeling

The AI-powered solution addresses critical format compatibility and integration points in ontology management:

Seamless Integration: Automated mapping connects directly to established ontologies, including NCIT, CHEBI, OBI, and EFO, via BioPortal and OLS APIs.Massive Scalability: Parallel processing and batch operations empower teams to execute large-scale ontology projects without performance limitations.Automated Hierarchies: The AI autonomously generates semantic relationships and parent-child hierarchies based on domain context and predefined relation vocabularies.Format Compatibility: The solution produces direct OWL/RDF exports with proper URIs, ensuring seamless downstream integration.

Unique Features include:

Multi-Source Integration: The solution combines BioPortal, OLS, and EMBL-EBI APIs to guarantee comprehensive ontology coverage.Intelligent Ranking System: The system uses AI-powered relevance scoring and justification for precise ontology mappings.Precise IRI Mapping: It ensures that each generated class is linked to the correct IRI, directly promoting semantic web compatibility.Human-in-the-Loop Design: The solution automates repetitive tasks while maintaining vital expert oversight.End-to-End Workflow: Users are guided through a complete pipeline, from initial domain knowledge input straight to exportable OWL files.Visual Knowledge Graph: An interactive graph visualization allows for intuitive relationship exploration and validation.Multi-Format Exports: Provides seamless export options in CSV, OWL, or HTML Ontograph formats for downstream use, collaboration, and visualization.

Strategic Value Across the Scientific Chain

This solution breaks down the traditional barriers of data structuring. Built on a robust backend of Python, LangChain, and leading LLM models, alongside a frontend framework using Next.js 15 and Cytoscape.js for graph visualization, the solution is highly adaptable. Furthermore, future optimization enhancements will include provisions for uploading user-defined classes or semi-ready ontologies.

About Zifo

Zifo is the leading global enabler of AI and data-driven enterprise informatics for science-driven organizations. With expertise spanning research, development, manufacturing, and clinical domains, Zifo serves a diverse range of industries including Pharma, Biotech, Chemicals, Food and Beverage, and more. Trusted by over 190 organizations worldwide, Zifo is the partner of choice for advancing digital scientific innovation.

For more information, visit www.zifornd.com; https://zifornd.com/practical-ai-blueprints/

Logo: https://mma.prnewswire.com/media/2731415/Zifo_Technologies_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/zifo-transforms-ontology-engineering-with-ai-powered-intelligent-automation-302758975.html

SOURCE Zifo Technologies

Technology

UNC-Chapel Hill establishes ‘Carolina in the Capital’ with new Washington, D.C. office

Published

13 minutes ago

April 30, 2026

CHAPEL HILL, N.C., April 30, 2026 /PRNewswire/ — The University of North Carolina at Chapel Hill has opened a new office in Washington, D.C., establishing an expanded presence for the University in the nation’s capital and creating exciting opportunities for students, faculty, staff and alumni.

Located at 101 Constitution Avenue NW, the 10,861-square-foot space – coined “Carolina in the Capital” – will support a variety of functions, including educational programming for undergraduate and graduate students, alumni relations and engagement with government partners.

As a leading R1 university, UNC-Chapel Hill annually attracts more than $1.6 billion to the state’s economy to fund research that creates a better quality of life for all its citizens. More than 60% of UNC-Chapel Hill’s total research funding comes from federal sponsors with the majority of that federal funding coming from the National Institutes of Health (NIH), which is based in the Washington area.

“Carolina in the Capital is a state-of-the-art facility that reflects our commitment to creating experiential learning opportunities for our students and faculty,” said Chancellor Lee H. Roberts. “The space is designed as an immersive learning environment where students can translate classroom knowledge into hands-on experience, which has never been more important. The facility also strengthens our ability to support engagement between our staff, alumni, policymakers and partners.”

Supporting students participating in Carolina’s Washington-based academic programs is a priority. For years, students and faculty have relied on temporary or borrowed spaces across the city. The new office provides a permanent home where students can gather, learn and build community while living and studying in Washington. A robust schedule of classes and events will fill the space throughout the year.

The Washington, D.C. region is home to the largest concentration of out-of-state Carolina alumni anywhere in the country. The new office creates a dedicated space to strengthen those connections and support networking, mentorship, professional development and community-building among D.C.-based Tar Heels.

The space will also serve as a platform to bring Carolina’s research and academic expertise into closer conversation with policymakers, industry leaders and member organizations. Carolina is the nation’s 11th largest university in the country based on research volume with primary federal funding coming from NIH and the National Science Foundation (NSF), both based in the D.C. area. Carolina is a proud member of the Association of American Universities (AAU) and the Association of Public & Land Grant Universities (APLU), which are both based in Washington.

The office is funded entirely through the UNC-Chapel Hill Foundation and does not use any state appropriations.

You can view additional photos of the space here.

Media Contact: UNC Media Relations, 919-445-8555, mediarelations@unc.edu

View original content to download multimedia:https://www.prnewswire.com/news-releases/unc-chapel-hill-establishes-carolina-in-the-capital-with-new-washington-dc-office-302758250.html

SOURCE University of North Carolina at Chapel Hill Office of Communications

Technology

Investing.com Acquires Stonki to Accelerate Its Entry into the Agentic AI Era

Published

13 minutes ago

April 30, 2026

The acquisition strengthens Investing.com’s AI capabilities, advancing a next-generation research assistant that can analyze markets, generate insights, and guide investors in real time

NEW YORK, April 30, 2026 /PRNewswire/ — Investing.com, one of the world’s largest financial platforms used by more than 60 million investors each month, today announced the acquisition of Stonki, an AI-powered investing assistant designed to help traders turn ideas into structured, actionable trading plans.

The move marks a major step in the company’s evolution toward agentic AI, strengthening its ability to deliver faster, deeper, and more actionable market insights to a growing base of more than 300,000 paying subscribers across its InvestingPro suite, the company’s premium subscription offering for advanced market data, tools, and AI-driven insights.

Over the past 12 months, nearly 3 million users have used WarrenAI, Investing.com’s AI-powered financial research assistant launched last year, to perform market analysis, making AI a central entry point into the platform’s ecosystem. With the addition of Stonki, the company is moving beyond traditional AI tools toward agentic systems that can proactively guide users through the investment process.

“We’re entering the age of agentic AI, where the technology moves beyond just answering questions to actively helping investors think, analyze, and act,” said Omer Shvili, CEO of Investing.com. “Bringing Stonki.ai into the fold accelerates our goal of building an agentic platform that will serve as a 24/7 analyst for our users. We are developing this to be more than just a tool; it will be a partner that identifies opportunities, tracks unfolding situations, and surfaces trade ideas even when the user isn’t active—giving our users the kind of edge that was previously only available to professional investors.”

Founded in 2025, Stonki is developing a new category of ‘agentic’ AI for investing, enabling users to turn investment ideas into fully defined strategies with entry and exit conditions, risk management rules, and continuous monitoring.

“We started Stonki because, as investors and traders ourselves, we knew how much time and focus it takes to stay on top of the market and properly manage a day trade, a swing trade, an investment idea, or a portfolio,” said Ulas Bilgenoglu and Itay Verkh, co-founders of Stonki. “We set out to build AI that could carry part of that load by continuously monitoring the market, turning ideas into structured strategies, and helping users make better decisions with clear entry and exit conditions, disciplined risk management, and ongoing tracking. Joining Investing.com gives us the scale, data, reach, and strong AI foundation to accelerate that vision. Together, we can create an experience where AI helps users stay ahead of the market, manage risk, and act with greater confidence.”

The acquisition expands Investing.com’s AI capabilities across both technical and fundamental investing workflows. Stonki’s technology is built around persistent, real-time intelligence, continuously monitoring markets, tracking user-defined strategies, and alerting investors when conditions align, rather than relying on one-off prompts or static analysis.

For active traders, the platform is evolving into a real-time analysis engine designed to support high-frequency decision-making with precision and speed. For long-term investors, it is becoming a central hub for research, enabling users to evaluate opportunities, set personalized alerts, and monitor portfolios based on their individual investment strategies.

Users will be able to define specific conditions, such as a stock crossing a long-term moving average, and have the AI continuously monitor the market, analyze relevant signals, and surface actionable insights in real time. The system will also review portfolios on an ongoing basis, helping investors avoid potential losses and uncover new opportunities aligned with their strategy.

This latest step builds on Investing.com’s broader strategy of expanding its AI-powered suite, including WarrenAI, ProPicks AI, and its recently launched AI Chart Analysis, all aimed at delivering faster, more accurate and more actionable insights to investors.

View original content:https://www.prnewswire.com/news-releases/investingcom-acquires-stonki-to-accelerate-its-entry-into-the-agentic-ai-era-302756588.html

SOURCE Investing.com